Anagliptin and sitagliptin as add-ons to metformin for patients with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, active-controlled, phase III clinical trial with a 28-week extension

Diabetes, Obesity and Metabolism

Volumn 17, Issue 5, 2015, Pages 511-515

  Jin, S M ^a   Park, S W ^a   Yoon, K H ^b   Min, K W ^c   Song, K H ^b   Park, K S ^d   Park, J Y ^e   Park, I B ^f   Chung, C H ^g   Baik, S H ^h   Choi, S H ⁱ   Lee, H W ^j   Lee, I K ^k   Kim, D M ^l   Lee, M K ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Eulji General Hospital   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Gachon University College of Medicine   (South Korea)

^g Yonsei University Wonju College of Medicine   (South Korea)

^h Korea University College of Medicine   (South Korea)

ⁱ Seoul National University Bundang Hospital   (South Korea)

^j Yeungnam University College of Medicine   (South Korea)

^k Kyungpook National University School of Medicine   (South Korea)

^l Hallym University   (South Korea)

more..

Author keywords

Antidiabetic drug; Diabetes care; DPP IV inhibitor; Incretin therapy

Indexed keywords

ANAGLIPTIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; PROINSULIN; SITAGLIPTIN; ANTIDIABETIC AGENT; HEMOGLOBIN A1C PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; LETTER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG COMBINATION; DRUG EFFECTS; PROCEDURES; SECRETION (PROCESS);

DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; PROINSULIN; PYRIMIDINES; SITAGLIPTIN PHOSPHATE;

EID: 84926149257     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12429     Document Type: Article

References (10)

1. Tsubamoto Y, Goto M. Preclinical and clinical aspects of the dipeptidyl peptidase-4 inhibitor anagliptin. Nihon Yakurigaku Zasshi 2013; 141: 339-349.
2. Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S etal. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1, 5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 2011; 19: 7221-7227.
3. Furuta S, Smart C, Hackett A, Benning R, Warrington S. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica 2013; 43: 432-442.
4. Rhee EJ, Lee WY, Min KW et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obes Metab 2013; 15: 523-530.
5. Kim YG, Hahn S, Oh TJ, Kwak SH, Park KS, Cho YM. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 2013; 56: 696-708.
6. Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 810-818.
7. Kim SA, Shim WH, Lee EH et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J 2011; 35: 159-165.
8. Lim S, An JH, Shin H et al. Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf) 2012; 77: 215-223.
9. Guerci B, Monnier L, Serusclat P et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab 2012; 38: 359-366.
10. Sakamoto M, Nishimura R, Irako T, Tsujino D, Ando K, Utsunomiya K. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol 2012; 11: 92.